NASDAQ:CLCDCoLucid Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CoLucid Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.52 0.00 (0.00 %) (As of 03/2/2017) Add Share Today's Range$46.53Now: $46.53▼$46.5350-Day Range N/A52-Week Range$5.26Now: $46.53▼$46.65VolumeN/AAverage Volume708,479 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for CoLucid Pharmaceuticals. Previous Next 2.3 Community Rank Outperform VotesCoLucid Pharmaceuticals has received 178 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCoLucid Pharmaceuticals has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentCoLucid Pharmaceuticals has received 54.71% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote “Outperform” if you believe CLCD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLCD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCoLucid Pharmaceuticals does not currently pay a dividend.Dividend GrowthCoLucid Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CoLucid Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.70% of the stock of CoLucid Pharmaceuticals is held by insiders.Percentage Held by Institutions64.17% of the stock of CoLucid Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:CLCD Previous Symbol CUSIPN/A CIK1348649 Webwww.colucid.com Phone+1-781-3652596Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive CLCD News and Ratings via Email Sign-up to receive the latest news and ratings for CLCD and its competitors with MarketBeat's FREE daily newsletter. CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions How were CoLucid Pharmaceuticals' earnings last quarter? CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) EPS for the quarter, meeting analysts' consensus estimates of ($0.79). View CoLucid Pharmaceuticals' earnings history. Has CoLucid Pharmaceuticals been receiving favorable news coverage? News articles about CLCD stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CoLucid Pharmaceuticals earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about CoLucid Pharmaceuticals. What other stocks do shareholders of CoLucid Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CoLucid Pharmaceuticals investors own include Gilead Sciences (GILD), Kite Pharma (KITE), Dova Pharmaceuticals (DOVA), Opko Health (OPK), Novavax (NVAX), Square (SQ), Ariad Pharmaceuticals (ARIA), Bausch Health Companies (BHC), Biopharmx (BPMX) and Biostar Pharmaceuticals (BSPM). When did CoLucid Pharmaceuticals IPO? (CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and William Blair was co-manager. What is CoLucid Pharmaceuticals' stock symbol? CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD." What is CoLucid Pharmaceuticals' stock price today? One share of CLCD stock can currently be purchased for approximately $46.53. What is CoLucid Pharmaceuticals' official website? The official website for CoLucid Pharmaceuticals is www.colucid.com. How can I contact CoLucid Pharmaceuticals? CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
